Trials / Completed
CompletedNCT00063479
Bisphosphonate Treatment of Osteogenesis Imperfecta
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 158 (planned)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 3 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this trial is to evaluate whether the investigational medication is safe, effective and has the ability to increase spine bone density in osteogenesis imperfecta (OI) patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic Acid |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2003-06-30
- Last updated
- 2017-06-01
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00063479. Inclusion in this directory is not an endorsement.